Canada leads the way in contraceptive compliance

    Organon Canada extends the Remind Me Today! reminder program

    TORONTO, Oct. 29 /CNW/ - Organon Canada has extended the Remind Me Today!
program - a free telephone-based reminder program designed to help women
remember their Linessa(R) or Nuvaring(R) contraceptives.
    In Canada, over 1.3 million women (Stat. Can., 2001) take oral
contraceptives everyday and there probably isn't a woman alive who hasn't
forgotten to take it at least once. Although the pill is over 99% effective
with perfect use (3 births/1000), approximately 80 births occur every year
through non-perfect use. (SOGC 2007)
    Organon Canada understands the important relationship between successful
healthcare outcomes and the use of communications technology. "We know how
busy women's lives are and we want to support them by providing them with a
reminder service. We are excited to be the first in the Canadian contraceptive
market to be offering women this innovative and practical solution, and we are
delighted by the response we have had since the launch of Remind Me Today! in
February 2007," explains Meena Bhogal, senior product manager for the Organon
Canada contraceptives portfolio.
    Canadian women using the daily Linessa(R) birth control pill, or
NuvaRing(R) - the one-a-month contraceptive ring - are taking advantage of
free reminder messages delivered to their home, office or cellular phones.
Remind Me Today! ( is tailored to each woman's needs.
Once registered, women choose the message they receive, the time the message
is delivered and, if they opt for cell phone reminders, whether it's a text or
voice message. Landline users receive voice messages to their home or office.
    Continuing its commitment to high quality lifestyle products for women,
Organon Canada has renewed its contract with Toronto's MEMOTEXT(R) to provide
the Remind Me Today! program until 2009 and program reminder messages until
    As the Canadian industry leader in 'personalized adherence solutions',
MEMOTEXT(R) helps healthcare professionals, payers, health care stakeholders
and providers boost bottom lines by supporting patient's efforts to comply
with prescribed treatment plans and creating a strong daily link between
stakeholders and patients.

    About Organon

    Organon creates, manufactures and markets innovative prescription
medicines that improve the health and quality of human life. Through a
combination of innovation and business partnerships, Organon seeks to leverage
its position as a leading biopharmaceutical company in each of its core
therapeutic fields: fertility, gynecology and selected areas of anesthesia. It
has extensive expertise in neuroscience and a rich and focused R&D program.
Research areas also include immunology and specific areas of oncology. Organon
products are distributed in over 100 countries worldwide, of which more than
50 have an Organon subsidiary. Organon is the human healthcare business unit
of Akzo Nobel.

    Safe Harbor Statement

    This press release may contain forward-looking statements. These
forward-looking statements, addressing without limitation such key issues as
growth strategy, future financial results, market positions, and product
development, are based on current expectations of future events and
circumstances and can be identified by the fact that they use words such as
"will", "anticipate", "estimate", "expect", "project", "intend", "plan",
"believe", "target", "forecast", and other words and terms of similar meaning
in connection with any discussion of future operating or financial performance
or business prospects.
    Such forward-looking statements should be carefully considered, and it
should be understood that many factors could cause forecasted and actual
results to differ from these forward-looking statements. Organon BioSciences
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or circumstances, or
    The forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Organon BioSciences'
business, particularly but without limitation including general industry
conditions and competition; economic conditions, such as interest rate and
currency exchange rate fluctuations; technological advances and patents
attained by competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and foreign health care
reforms and governmental laws and regulations; and trends toward health care
cost containment.

For further information:

For further information: Danielle Adler, Vice President, Business
Development,, 1-877-636-6898, (647) 430-8233, Direct:
(416) 435-8131; Meena Bhogal, Sr. Product Manager, Contraception, Organon
Canada,, (416) 290-2156

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890